Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Central Corneal Swelling With Silicone Hydrogel Materials

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02328937
Recruitment Status : Completed
First Posted : December 31, 2014
Results First Posted : January 30, 2017
Last Update Posted : June 19, 2018
Sponsor:
Information provided by (Responsible Party):
Johnson & Johnson Vision Care, Inc.

Brief Summary:
This is a prospective, single site, unmasked, cross-over study with three silicone hydrogel contact lenses comparing central corneal swelling.

Condition or disease Intervention/treatment Phase
Corneal Swelling Device: etafilcon A Device: lotrafilcon B Device: comfilcon A Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Daily Wear Central Corneal Swelling With Etafilcon A and 2 Silicone Hydrogel Materials
Study Start Date : November 2014
Actual Primary Completion Date : April 2015
Actual Study Completion Date : April 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eye Wear

Arm Intervention/treatment
Active Comparator: etafilcon A/lotrafilcon B/comfilcon A
Subjects that were randomized to receive the etafilcon A lens 1st, the lotrafilcon B lens 2nd and the comfilcon A lens 3rd.
Device: etafilcon A
spherical hydrophilic soft contact lens worn in a daily wear modality
Other Name: Investigational Soft Contact Lens -

Device: lotrafilcon B
Device: comfilcon A
Active Comparator: etafilcon A/comfilcon A/lotrafilcon B
Subjects that were randomized to receive the etafilcon A lens 1st, the comfilcon A lens 2nd and the lotrafilcon B lens 3rd.
Device: etafilcon A
spherical hydrophilic soft contact lens worn in a daily wear modality
Other Name: Investigational Soft Contact Lens -

Device: lotrafilcon B
Device: comfilcon A
Active Comparator: comfilcon A/etafilcon A/lotrafilcon B
Subjects that were randomized to receive the comfilcon A lens 1st, the etafilcon A lens 2nd and the lotrafilcon B lens 3rd.
Device: etafilcon A
spherical hydrophilic soft contact lens worn in a daily wear modality
Other Name: Investigational Soft Contact Lens -

Device: lotrafilcon B
Device: comfilcon A
Active Comparator: comfilcon A/lotrafilcon B/etafilcon A
Subjects that were randomized to receive the comfilcon A lens 1st, the lotrafilcon B lens 2nd and the etafilcon A lens 3rd.
Device: etafilcon A
spherical hydrophilic soft contact lens worn in a daily wear modality
Other Name: Investigational Soft Contact Lens -

Device: lotrafilcon B
Device: comfilcon A
Active Comparator: lotrafilcon B/etafilcon A/comfilcon A
Subjects that were randomized to receive the lotrafilcon B lens 1st, the etafilcon A lens 2nd and the comfilcon A lens 3rd.
Device: etafilcon A
spherical hydrophilic soft contact lens worn in a daily wear modality
Other Name: Investigational Soft Contact Lens -

Device: lotrafilcon B
Device: comfilcon A
Active Comparator: lotrafilcon B/comfilcon A/etafilcon A
Subjects that were randomized to receive the lotrafilcon B lens 1st, the comfilcon A lens 2nd and the etafilcon A lens 3rd.
Device: etafilcon A
spherical hydrophilic soft contact lens worn in a daily wear modality
Other Name: Investigational Soft Contact Lens -

Device: lotrafilcon B
Device: comfilcon A



Primary Outcome Measures :
  1. Central Corneal Swelling [ Time Frame: 6-8 Hours Post lens insertion ]
    Corneal swelling measurements were taken in the right eye during slit lamp evaluations, 6-8 hours post lens insertion. The average corneal swelling per lens was reported.


Secondary Outcome Measures :
  1. Limbal Redness [ Time Frame: 6-8 hours post lens insertion ]
    Limbal redness was assessed in both eyes using a slit lamp, 6-8 hours post lens insertion. Redness was assessed in 4 regions of the eye (nasal, temporal, inferior and superior) and was graded with a 5-point scale (i.e. Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe). For each region (nasal, temporal, inferior and superior) the average grade was calculated by lens. The Total Grade was then calculated by summing all the average grade for each region. The regional average grade ranges from 0 to 4. The total Grade ranges from 0 to 16.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. The participant must be at leat 18 years old or older and no greater than 65 years old. Children younger than18 will likely no be able to come back and forth to the clinic during the typical work week as outlined in the above (due to school schedules) and thus not be able to adhere to the protocol.
  2. The participant must be a current soft contact lens wearer who routinely wears lenses at least 6-8 hours per day and at least 4 days per week for at least the past 3 months.
  3. Refraction suitable for spherical soft contact lens powers between -1.00 and -6.00 D the participant must be correctable to 20/30 or better at distance with both eyes with dispensed contact lenses.
  4. The participant must be free of any active anterior segment disorders that would preclude safe contact lens wear. Active anterior segment disorders and evidence of central microbial keratitis are not allowed. However, evidence of past CLPU will be allowed so long as no more than 3 such scars are detected bilaterally. Evidence of more than 3 CLPU-like scars places excessive risk on the participant for subsequent CIE.
  5. The participant must be correctable to 20/25 or better in each eye with spectacles. Amblyopia will be excluded.
  6. Flat and steep corneal curvatures from keratometry readings must be between 39.00 and 48.50 D, respectively. Corneal curvatures outside this range may be indicative of a disease state, and the participants are not expected to comfortably wear the study lenses.
  7. The participant must own or agree to purchase a pair of spectacles that can be worn when lenses are removed, during the washout periods, or in case of ocular discomfort or emergency.

Exclusion Criteria:

  1. The participant has worn rigid gas permeable contact lenses within the last 30 days or PMMA lenses within the past 12 months. These lenses can transiently alter the corneal shape and influence the fitting of soft contact lenses or alter endothelial cell morphology.
  2. The participant has an immunocompromising disease or any other systemic disease that in the investigator's opinion will affect ocular health or increase risk during daily contact lens wear.
  3. The participant is taking any medication that in the investigator's opinion will affect ocular physiology or study participation.
  4. The participant has an ocular disease or condition such as aphakia, clinically significant corneal dystrophies, corneal edema, external ocular infection, iritis, or had any anterior segment surgery.
  5. The participant is taking any ocular medications. If a participant was previous taking any ocular medications, the medications must have been discontinued at least 2 weeks prior to enrollment.
  6. The participant must have less than or equal to grade 2 on any of the slit lamp observations of: upper tarsal papilla, corneal staining, corneal neovascularization, conjunctival injection, and lid erythema or scales.
  7. The participant is currently pregnant or lactating. Participant who become pregnant during the study will be discontinued.
  8. An employee or member of the UHCMC Eye Institute or a family member of any study personnel.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02328937


Locations
Layout table for location information
United States, Ohio
Cleveland, Ohio, United States, 44124
Sponsors and Collaborators
Johnson & Johnson Vision Care, Inc.
Layout table for additonal information
Responsible Party: Johnson & Johnson Vision Care, Inc.
ClinicalTrials.gov Identifier: NCT02328937    
Other Study ID Numbers: CR-5550
First Posted: December 31, 2014    Key Record Dates
Results First Posted: January 30, 2017
Last Update Posted: June 19, 2018
Last Verified: December 2016